Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Professor, Pharmacy Practice, Medicine and Pediatrics

Associate Director

NYS Center of Excellence in Bioinformatics and Life Sciences

University at Buffalo

Buffalo, NY

Topics of Professional Interest:


  • HIV and HCV Drug Development and Clinical Pharmacology
  • Global Health, Infectious Diseases and Bioinformatics
  • Translational Pharmacology, Health Information Technology and Nanomedicine
Current Professional Summary:

Gene D. Morse, PharmD, FCCP, BCPS, is professor of Pharmacy Practice, Medicine and Pediatrics and associate director of the New York State Center of Excellence in Bioinformatics and Life Sciences at the University at Buffalo (UB), State University of New York. Dr. Morse is also a Research professor of Medicine, Pharmacology and Physiology at the University of Rochester (UR) and an investigator in the UR Center for AIDS Research and the NIAID Clinical Trials Unit at UR. Dr. Morse has been actively involved in HIV clinical pharmacology research since the introduction of antiretrovirals in 1986. Dr. Morse has National Institute of Allergy and Infectious Diseases (NIAID) support for the UB AIDS Clinical Trials Group (ACTG) Pharmacology Specialty Laboratory and a contract for the HIV Clinical Pharmacology Quality Assurance Program. These programs integrate with the NIH Fogarty International Center AIDS International Training and Research Program, which Dr. Morse directs with the University of Zimbabwe in Clinical Pharmacology and Implementation Research. Dr. Morse also directs the UB HIV Clinical Pharmacology Laboratory, which has gained an international reputation for its work in bioanalysis, pharmacokinetics, drug interactions and pharmacogenomics. Dr. Morse is the director of the ACTG Laboratory Center’s Clinical Pharmacology Core and a member of the ACTG Viral Hepatitis Transformative Science Group. Dr. Morse holds leadership positions within the UB Clinical and Translational Research Consortium and the University of Rochester Clinical and Translational Sciences Institute.

Committees and Organizations:

2012 – present    Member, AACP Volwiler Research Achievement Award Selection Committee

2012 – present    Member, New York State Department of Health, AIDS Institute, Pharmacy Advisory Committee

2010 – present    Member, American Society of Nanomedicine

2010 – present    ACCP Abstract Reviewer – Original Research, Clinical Pharmacy Forum, and Student/Resident Research-in-Progress

2010 – present    Member, Steering Committee of the NY HIV Research Centers Consortium

2010 – present    Co-Director, UNYTE Translational Research Network – University of Rochester CTSA

2009 – present    Consultant, FDA Antiretroviral Drugs Advisory Committee (AVDAC)

Honors and Awards:

2013       ACCP Research Institute Trustee Nominee (Spring 2014 Ballot)

2012       Amer Assoc of Colleges of Pharmacy, Volwiler Research Achievement Award

2010       UB Council on International Studies and Programs Award for Outstanding Contributions to International Education

  • University of Albany, SUNY, BS, Biology (1976)
  • University of Buffalo, SUNY, BS, Pharmacy (1980)
  • Moses Cone Memorial Hospital, Greensboro, NY, Resident, Hospital Pharmacy (1981)
  • University of Buffalo, SUNY, PharmD (1983)
  • University of Buffalo, SUNY, Fellow, Clinical Pharmacokinetics (1984)
Selected Publications:
  1. Mudzviti T, Sibanda M, Gavi S, Maponga CC, Morse GD. Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program. J Infect Dev Ctries. 2012 Nov 26;6(11):806-8. doi: 10.3855/jidc.1908. PMCID: PMC3535441
  2. Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW. Genome-Wide Association Study of Plasma Efavirenz Pharmacokinetics in AIDS Clinical Trials Group Protocols Implicates Several CYP2B6 Variants. Pharmacogenet and Genomics. 2012 Dec;22(12):858-867.. [Epub ahead of print] PMID: 23080225
  3. Oramasionwu CU, Koeller JM, Lawson KA, Brown CM, Morse GD, Frei CR. The State of Disparities in Opportunistic Infection Prophylaxis for Blacks with HIV/AIDS. Med Care. 2012 Nov. 50(11):920-7. PMCID: PMC3470654
  4. Ribaudo HJ, Daar ES, Tierney C, Morse GD, Mollan K, Sax PE, Fischl MA, Collier AC, Haas DW. Impact of UGT1A1 Gilbert Variant on Discontinuation of Ritonavir-boosted Atazanavir in AIDS Clinical Trials Group Study A5202. J Infect Dis. 2013 Feb;207(3):420-425. [Epub 2012 Nov 12] PMCID: PMC3537445
  5. DiFrancesco R, Maduke G, Patel R, Taylor CR, Morse GD. Antiretroviral bioanalysis methods of tissues and body biofluids. Bioanalysis. 2013 Feb;5(3):351-68. doi: 10.4155/bio.12.319. PMID: 23394701
  6. Zhang X, Tierney C, Albrecht M, Demeter LM, Morse GD, DiFrancesco R, Dykes C, Jiang H, Haas DW. Discordant Associations between SLCO1B1 21TàC and Plasma Levels of Ritonavir-boosted Protease Inhibitors in AIDS Clinical Trials Group Study A5146.Ther Drug Monit. 2013 Apr;35(2):209-16. doi: 10.1097/FTD.0b013e318280d0ad. PMCID: PMC3603284
  7. DiFrancesco R, Tooley K, Rosenkranz SL, Siminski S, Taylor CR, Pande P, Morse GD. Clinical Pharmacology Quality Assurance for HIV and Related Infectious Diseases Research. Clinical Pharmacology & Therapeutics. 2013 Jun;93(6):479-82. PMID: 23588323
  8. DiFrancesco R, Rosenkranz SL, Taylor CR, Pande PG, Siminski SM, Jenny RW, Morse GD. Clinical Pharmacology Quality Assurance (CPQA) Program: Longitudinal Analysis of Antiretroviral (ARV) Proficiency Testing for International Laboratories. Ther Drug Monit. Accepted.
  9. McCance-Katz EF, Gruber V, Beatty G, Lum PJ, Ma Q, DiFrancesco R, Hochreiter J, Wallace PK, Morse GD. Interaction of Disulfiram with Efavirenz, Ritonavir or Atazanavir. Am J Addict. Accepted.
  10. Mikula J, Sawyer JR, Ma Q, Sulaiman AS, Hsiao CB, Morse GD. Comparative effectiveness of darunavir 1,200 mg daily and approved dosing strategies for protease inhibitor-experienced patients. AIDS Res Treat. 2013 June. Vol. 2013, Article ID 687176, 4 pages. doi:10.1155/2013/687176


Hepatitis C Virus Infection: Looking Beyond the Interferon Alfa Era